Paper Details

  1. Home
  2. Paper Details

Effects of rabeprazole on bone metabolic disorders in a gastrectomized rat model.

Author: FujimuraTakashi, FushidaSachio, HigashiYuki, HiroseAtsushi, KinoshitaJun, MiyashitaTomoharu, NakamuraKeishi, NinomiyaItasu, OhtaTetsuo, OkamotoKoichi, OyamaKatsunobu, TajimaHidehiro, TakamuraHiroyuki, TsukadaTomoya, YamasakiYuki

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the effects of the proton pump inhibitor (PPI) rabeprazole on skeletal metabolism in gastrectomized rats. Rabeprazole ameliorated the decrease in bone mineral density but did not improve bone strength. These findings suggest that rabeprazole does not exacerbate bone metabolic disorders in gastrectomized rats.
Paper Details　
Original Abstract of the Article :
Proton pump inhibitors (PPIs) are frequently prescribed to patients with gastroesophageal reflux disease; however, the number of bone fractures reportedly increased in these patients. Although PPIs have been shown to inhibit the bone resorption by osteoclasts, the effect of PPIs on skeletal metaboli...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906904/

データ提供：米国国立医学図書館（NLM）

Rabeprazole and Bone Metabolism: Exploring the Connection

This study takes us into the realm of proton pump inhibitors (PPIs), commonly prescribed medications for gastroesophageal reflux disease. It's like a desert traveler encountering a mirage, where the appearance of water can be deceptive. The study examines the effect of rabeprazole, a PPI, on bone metabolism in a gastrectomized rat model, exploring the potential for bone complications associated with PPI use.

Navigating the Desert of Bone Health

The authors investigate the impact of rabeprazole on bone mineral density (BMD) and other markers of bone metabolism in a gastrectomized rat model. They find that rabeprazole does not exacerbate bone metabolic disorders, suggesting that it may actually have a protective effect on bone health. It's like finding a hidden oasis in the desert, offering a source of hydration and nourishment for bone tissue.

Protecting Bone Health: A Journey Through the Desert

This study provides valuable insights into the potential effects of PPIs on bone metabolism, suggesting that rabeprazole may not pose a significant risk to bone health in patients with gastrectomy. It encourages further research into the long-term effects of PPIs on bone health and the development of strategies for managing potential risks. It's like building a sturdy caravan to withstand the challenges of navigating the desert of bone health.

Dr.Camel's Conclusion

This study suggests that rabeprazole, a PPI, may not pose a significant risk to bone health in patients with gastrectomy. It encourages further research into the long-term effects of PPIs on bone health and the development of strategies for managing potential risks, ensuring a safe and healthy journey through the desert of gastrointestinal and bone health.

Date :
  1. Date Completed n.d.
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

27330752

DOI: Digital Object Identifier

PMC4906904

Related Literature

Article Analysis
・Effects of rabeprazole
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.